Literature DB >> 16721811

Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas.

Susanne Haas1, Christiane Pierl, Volker Harth, Beate Pesch, Sylvia Rabstein, Thomas Brüning, Yon Ko, Ute Hamann, Christina Justenhoven, Hiltrud Brauch, Hans-Peter Fischer.   

Abstract

The potential to metabolize endogenous and exogenous substances may influence breast cancer development and tumor growth. Therefore, the authors investigated the protein expression of Glutathione S-transferase (GST) isoforms and cytochrome P450 (CYP) known to be involved in the metabolism of steroid hormones and endogenous as well as exogenous carcinogens in breast cancer tissue to obtain new information on their possible role in tumor progression. Expression of GST pi, mu, alpha and CYP1A1/2, 1A2, 3A4/5, 1B1, 2E1 was assessed by immunohistochemistry for primary breast carcinomas of 393 patients from the German GENICA breast cancer collection. The percentages of positive tumors were 50.1 and 44.5% for GST mu and CYP2E1, and ranged from 13 to 24.7% for CYP1A2, GST pi, CYP1A1/2, CYP3A4/5, CYP1B1. GST alpha was expressed in 1.8% of tumors. The authors observed the following associations between strong protein expression and histopathological characteristics: GST expression was associated with a better tumor differentiation (GST mu, p = 0.018) and with reduced lymph node metastasis (GST pi, p = 0.02). In addition, GST mu expression was associated with a positive estrogen receptor and progesterone receptor status (p < 0.001). CYP3A4/5 expression was associated with a positive nodal status (p = 0.018). Expression of CYP1B1 was associated with poor tumor differentiation (p = 0.049). Our results demonstrate that the majority of breast carcinomas expressed xenobiotic and drug metabolizing enzymes. They particularly suggest that GST mu and pi expression may indicate a better prognosis and that strong CYP3A4/5 and CYP1B1 expression may be key features of nonfavourable prognosis. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721811     DOI: 10.1002/ijc.21915

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  The fungal glutathione S-transferase system. Evidence of new classes in the wood-degrading basidiomycete Phanerochaete chrysosporium.

Authors:  Mélanie Morel; Andrew A Ngadin; Michel Droux; Jean-Pierre Jacquot; Eric Gelhaye
Journal:  Cell Mol Life Sci       Date:  2009-08-07       Impact factor: 9.261

Review 2.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Authors:  Ogheneochukome Lolodi; Yue-Ming Wang; William C Wright; Taosheng Chen
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

3.  Identification of mammary epithelial cells subject to chronic oxidative stress in mammary epithelium of young women and teenagers living in USA: implication for breast carcinogenesis.

Authors:  Judith Weisz; Debra A Shearer; Erin Murata; Susan D Patrick; Bing Han; Arthur Berg; Gary A Clawson
Journal:  Cancer Biol Ther       Date:  2012-01-15       Impact factor: 4.742

4.  CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET).

Authors:  Ranjana Mitra; Zhijun Guo; Monica Milani; Clementina Mesaros; Mariangellys Rodriguez; Julia Nguyen; Xianghua Luo; Duncan Clarke; Jatinder Lamba; Erin Schuetz; David B Donner; Narender Puli; John R Falck; Jorge Capdevila; Kalpna Gupta; Ian A Blair; David A Potter
Journal:  J Biol Chem       Date:  2011-03-14       Impact factor: 5.157

5.  CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.

Authors:  Hamid Zia; Graeme I Murray; Carrie A Vyhlidal; J Steven Leeder; Ahmed E Anwar; Marilyn M Bui; Atif A Ahmed
Journal:  Int J Exp Pathol       Date:  2015-02-09       Impact factor: 1.925

6.  CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

Authors:  Monika Pawłowska; Ewa Augustin; Zofia Mazerska
Journal:  Acta Pharmacol Sin       Date:  2013-12-02       Impact factor: 6.150

7.  Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women.

Authors:  Lori C Sakoda; Christie R Blackston; Kan Xue; Jennifer A Doherty; Roberta M Ray; Ming Gang Lin; Helge Stalsberg; Dao Li Gao; Ziding Feng; David B Thomas; Chu Chen
Journal:  Breast Cancer Res Treat       Date:  2007-07-12       Impact factor: 4.872

8.  Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.

Authors:  Argun Akcakanat; Xiaofeng Zheng; Christian X Cruz Pico; Tae-Beom Kim; Ken Chen; Anil Korkut; Aysegul Sahin; Vijaykumar Holla; Emily Tarco; Gopal Singh; Senthil Damodaran; Gordon B Mills; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam
Journal:  Clin Cancer Res       Date:  2021-03-29       Impact factor: 12.531

9.  CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Authors:  Gwladys Zabouo; Anne-Marie Imbert; Jocelyne Jacquemier; Pascal Finetti; Thomas Moreau; Benjamin Esterni; Daniel Birnbaum; François Bertucci; Christian Chabannon
Journal:  Breast Cancer Res       Date:  2009-01-05       Impact factor: 6.466

10.  Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women.

Authors:  Carolyn J Crandall; Mary E Sehl; Sybil L Crawford; Ellen B Gold; Laurel A Habel; Lesley M Butler; Maryfran R Sowers; Gail A Greendale; Janet S Sinsheimer
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.